Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
Welcome to Abbott's third quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants questions asked during the question-and-answer session,
Abbott Labs beats Q3 sales and earnings expectations, raises full-year outlook
Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the company’s medical-devices business.
Abbott Laboratories Q3 Profit Increases, Beats Estimates
Abbott Laboratories (ABT) revealed earnings for its third quarter that increased from the same period last year and beat the Street
Abbott Laboratories posts Q3 beat, raises profit forecast
Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings beat driven by strong demand for the company's medical devices. Morning Brief Hosts Seana Smith and Brad Smith break down what investors need to know.
Abbott: Q3 Earnings Snapshot
On a per-share basis, the Abbott Park, Illinois-based company said it had profit of 94 cents. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.20 per share.
Abbott Stock Gains on Q3 Earnings Beat, Margins Expand
Abbott Laboratories ABT reported third-quarter 2024 adjusted earnings per share (EPS) of $1.21, which beat the Zacks Consensus Estimate by 0.8%. The figure also improved 6.1% from the prior-year quarter’s level.
ABT Earnings: Strong Medical Device Sales Help Abbott Beat Q3 Estimates
Abbott ($ABT) reported better-than-expected third-quarter results on Wednesday. The medical devices and healthcare company’s sales increased by
Abbott Laboratories Narrows Full-Year Earnings Outlook Range Following Third-Quarter Beat
Abbott Laboratories (ABT) reported better-than-expected third-quarter results on Wednesday amid double-digit revenue growth in its medical devices segment, while the healthcare company narrowed its full-year earnings outlook range.
Abbott raises earnings outlook as MedTech, Pharma drive Q3 beat
Abbott Laboratories (NYSE:ABT) increased its full-year earnings guidance on Tuesday after its financials for Q3 2024 exceeded Wall Street's forecasts, thanks mainly to the strength in its Pharma and MedTech segments.
Benzinga.com1d
Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast
Abbott's Q3 sales reached $10.64B, beating the consensus of $10.55B ... beating the analyst estimates of $1.20. Also Read ...
Abbott Laboratories: It's No Longer A Buy For Now
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...
High-Quality Abbott Stock: Corporate Growth That Pays You to Own It
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Diabetes Products To Drive Abbott's Q3
With an in-line performance expected in Q3, ABT stock may trade sideways next week. However, we would watch out for its ...
Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...
Abbott Laboratories: Balanced Prospects Lead to Hold Recommendation Amid Market Adjustments
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...
Yahoo Finance6d
Abbott (ABT) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
In its upcoming report, Abbott (ABT) is predicted by Wall Street analysts to post quarterly earnings of $1.20 per share, reflecting an increase of 5.3% compared to the same period last year.